Merck (MRK) Short-term Investments (2009 - 2026)

Merck has disclosed Short-term Investments across 17 years of filings, most recently posting $375.0 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 37.4% year-over-year to $375.0 million; the TTM figure through Mar 2026 stood at $375.0 million (down 37.4% YoY), while the FY2024 annual figure was $447.0 million, up 77.38% from the prior year.
• Short-term Investments rose to $375.0 million in Q1 2026, from $45.0 million in the prior quarter.
• Over the last five years, Short-term Investments for MRK reached as high as $718.0 million in Q2 2023 and fell as low as $40.0 million in Q1 2024.
• The 5-year median for Short-term Investments is $375.0 million (2026), against an average of $361.0 million.
• Annual changes were most pronounced in 2024 — Short-term Investments slumped 94.12% — and 2025, when it surged 1397.5%.
• A 5-year view of Short-term Investments shows it stood at $498.0 million in 2022, then slumped by 49.4% to $252.0 million in 2023, then jumped by 77.38% to $447.0 million in 2024, then tumbled by 89.93% to $45.0 million in 2025, then soared by 733.33% to $375.0 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $375.0 million, $45.0 million, and $615.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.